Relative to control. n = 3, significant difference,*p,0.05; ns, not significant. (B) Induction of inflammatory cytokine mRNA in infected BMDMs as above described. Results are mean fold change 6 SEM, n = 3, significant difference, *p,0.05; ns, not significant. doi:10.1371/journal.pone.0052117.ginhibitory effect on metastatic growth of lung tumor, as revealed by macroscopy and microscopy examination (Fig. 2A,B). We also assessed the survival times of tumor injected mice that were treated with CDA-2 by NT-157 chemical information Kaplan-Meier survival analysis. Mice survival times were assessed and showed that the life spans of tumorbearing mice were prolonged when given different concentration of CDA-2 treatment (Fig. 1C). There also had significant difference in the survival rate of different concentration CDA-2treated tumor-bearing mice (Fig. 1C). These results confirm those obtained by examining tumor multiplicity, maximal tumor sizes, H E staining from lung metastatic carcinomas models.CDA-2 Reduced Proliferation and Induced Apoptosis in Lung Cancer CellsNext, to investigate whether CDA-2-induced change in lung tumour burden was due to altered cell proliferation or apoptosis, we examined cell proliferation by immuno-histochemical analysis of Ki-67 and cell apoptosis by in situ terminal-transferase dUTPmediated nick end labeling (TUNEL) assay. 26105 LLC cells were injected into mice and 14 days late 2000 mg/kg CDA-2, 800 mg/kg PG or PBS was administered as above for 5 days. Consistent with the changes in lung tumour burden, Ki-67-positive cells were lower in CDA-2 or PG-treated tumors as compared to tumors of PBS-treated animals (Fig. 3A). Conversely, apoptosis was significantly upregulated after CDA-2 or PG treatment, whereas very little apoptosis 
was seen after PBS treatment (Fig. 3B). We examined some proteins and genes known to be involved in cell proliferation and apoptosis. Tumors were carefully microdissected using needles from lungs, lysed, and examined by immunoblotting. In contrast to PBS treatment group, expression of the antiapoptotic proteins Bcl-2, PD-168393 supplier Bcl-XL, cIAP1, and Survivin were strongly reduced in response to CDA-2 treatment (Fig. 3C). CDA-2 treatment also decreased the expression of proliferating cell nuclear antigen (PCNA), another S phase marker of cell cycle (Fig. 3C). Immunoblot analysis of tumor lysates of mice also revealed downregulation of Bcl-2, Bcl-XL, cIAP1, and Survivin as well as PCNA in lung tumors after PG treatment (Fig. 3C). These results correlate with those observed by the analysis of Ki-67 and TUNEL.CDA-2 Inhibits Lung Cancer DevelopmentCDA-2 Inhibits NF-kB Activation and Pulmonary Inflammation in the Lung of MiceIt has been shown that NF-kB activation plays a pivotal role in regulation of inflammatory and immune response, apoptosis, and oncogenesis which is associated with inflammation-promoting tumor growth [19,20]. To elucidate the mechanisms of tumorinhibiting effect of CDA-2, we first compared the 12926553 NF-kB activation of dissected cancer from mice with CDA-2, PG or PBS treatment. Of note, resected tissue contained tumor tissue including tumor and inflammatory cells. Nuclear extracts were prepared and NF-kB activation examined by EMSA. As shown in Fig. 4A, CDA-2 treatment significantly decreased NF-kB DNA binding activity compared with the control after 5 days 2000 mg/ kg CDA-2 treatment. Importantly, NF-kB DNA binding activity also were strongly inhibited in response to CDA-2 treatment in alveolar macrophages of bronchoalveo.Relative to control. n = 3, significant difference,*p,0.05; ns, not significant. (B) Induction of inflammatory cytokine mRNA in infected BMDMs as above described. Results are mean fold change 6 SEM, n = 3, significant difference, *p,0.05; ns, not significant. doi:10.1371/journal.pone.0052117.ginhibitory effect on metastatic growth of lung tumor, as revealed by macroscopy and microscopy examination (Fig. 2A,B). We also assessed the survival times of tumor injected mice that were treated with CDA-2 by Kaplan-Meier survival analysis. Mice survival times were assessed and showed that the life spans of tumorbearing mice were prolonged when given different concentration of CDA-2 treatment (Fig. 1C). There also had significant difference in the survival rate of different concentration CDA-2treated tumor-bearing mice (Fig. 1C). These results confirm those obtained by examining tumor multiplicity, maximal tumor sizes, H E staining from lung metastatic carcinomas models.CDA-2 Reduced Proliferation and Induced Apoptosis in Lung Cancer CellsNext, to investigate whether CDA-2-induced change in lung tumour burden was due to altered cell proliferation or apoptosis, we examined cell proliferation by immuno-histochemical analysis of Ki-67 and cell apoptosis by in situ terminal-transferase dUTPmediated nick end labeling 
(TUNEL) assay. 26105 LLC cells were injected into mice and 14 days late 2000 mg/kg CDA-2, 800 mg/kg PG or PBS was administered as above for 5 days. Consistent with the changes in lung tumour burden, Ki-67-positive cells were lower in CDA-2 or PG-treated tumors as compared to tumors of PBS-treated animals (Fig. 3A). Conversely, apoptosis was significantly upregulated after CDA-2 or PG treatment, whereas very little apoptosis was seen after PBS treatment (Fig. 3B). We examined some proteins and genes known to be involved in cell proliferation and apoptosis. Tumors were carefully microdissected using needles from lungs, lysed, and examined by immunoblotting. In contrast to PBS treatment group, expression of the antiapoptotic proteins Bcl-2, Bcl-XL, cIAP1, and Survivin were strongly reduced in response to CDA-2 treatment (Fig. 3C). CDA-2 treatment also decreased the expression of proliferating cell nuclear antigen (PCNA), another S phase marker of cell cycle (Fig. 3C). Immunoblot analysis of tumor lysates of mice also revealed downregulation of Bcl-2, Bcl-XL, cIAP1, and Survivin as well as PCNA in lung tumors after PG treatment (Fig. 3C). These results correlate with those observed by the analysis of Ki-67 and TUNEL.CDA-2 Inhibits Lung Cancer DevelopmentCDA-2 Inhibits NF-kB Activation and Pulmonary Inflammation in the Lung of MiceIt has been shown that NF-kB activation plays a pivotal role in regulation of inflammatory and immune response, apoptosis, and oncogenesis which is associated with inflammation-promoting tumor growth [19,20]. To elucidate the mechanisms of tumorinhibiting effect of CDA-2, we first compared the 12926553 NF-kB activation of dissected cancer from mice with CDA-2, PG or PBS treatment. Of note, resected tissue contained tumor tissue including tumor and inflammatory cells. Nuclear extracts were prepared and NF-kB activation examined by EMSA. As shown in Fig. 4A, CDA-2 treatment significantly decreased NF-kB DNA binding activity compared with the control after 5 days 2000 mg/ kg CDA-2 treatment. Importantly, NF-kB DNA binding activity also were strongly inhibited in response to CDA-2 treatment in alveolar macrophages of bronchoalveo.
